These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31005492)

  • 1. Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis.
    Seung KJ; Hewison C
    Lancet Glob Health; 2019 Jun; 7(6):e706. PubMed ID: 31005492
    [No Abstract]   [Full Text] [Related]  

  • 2. Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.
    Weyer K; Falzon D; Jaramillo E
    Bull World Health Organ; 2018 Oct; 96(10):667-667A. PubMed ID: 30455511
    [No Abstract]   [Full Text] [Related]  

  • 3. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.
    Sotgiu G; Tiberi S; D'Ambrosio L; Centis R; Zumla A; Migliori GB
    Lancet; 2016 Jun; 387(10037):2486-7. PubMed ID: 27353670
    [No Abstract]   [Full Text] [Related]  

  • 4. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
    Varaine F; Guglielmetti L; Huerga H; Bonnet M; Kiria N; Sitienei JK; Rich M; Mitnick CD
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1028-1029. PubMed ID: 27739887
    [No Abstract]   [Full Text] [Related]  

  • 5. Is Shorter Treatment Regimen for Multidrug-resistant Tuberculosis feasible in Indian Children?
    Shah I
    Indian Pediatr; 2017 Feb; 54(2):160. PubMed ID: 28285296
    [No Abstract]   [Full Text] [Related]  

  • 6. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
    Lange C; Duarte R; Fréchet-Jachym M; Guenther G; Guglielmetti L; Olaru ID; Oliveira O; Rumetshofer R; Veziris N; van Leth F;
    Am J Respir Crit Care Med; 2016 Oct; 194(8):1029-1031. PubMed ID: 27685538
    [No Abstract]   [Full Text] [Related]  

  • 7. Revolutionary new treatment regimens for multidrug-resistant tuberculosis.
    McHugh TD; Honeyborne I; Lipman M; Zumla A
    Lancet Infect Dis; 2019 Mar; 19(3):233-234. PubMed ID: 30833051
    [No Abstract]   [Full Text] [Related]  

  • 8. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    van der Werf MJ; Hollo V; Ködmön C; Dara M; Catchpole M
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shorter regimen for multi drug resistant tuberculosis cures more than 80% of patients.
    Cousins S
    BMJ; 2016 Oct; 355():i5807. PubMed ID: 27789468
    [No Abstract]   [Full Text] [Related]  

  • 10. Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone.
    Singh PK; Jain A
    Emerg Infect Dis; 2019 Sep; 25(9):1760-1762. PubMed ID: 31441763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing the game for multidrug-resistant tuberculosis.
    Ghanashyam B
    Lancet; 2016 Mar; 387(10024):1149-50. PubMed ID: 27025324
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach.
    Schaaf HS
    Indian J Pediatr; 2019 Aug; 86(8):717-724. PubMed ID: 30656560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistant TB: fully oral regimens should help improve compliance, says WHO.
    Murphy D
    BMJ; 2018 Aug; 362():k3610. PubMed ID: 30131439
    [No Abstract]   [Full Text] [Related]  

  • 14. World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
    Cox V; Furin J
    Int J Tuberc Lung Dis; 2017 Dec; 21(12):1211-1213. PubMed ID: 29297439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Revised National Tuberculosis Control Programme in India: time for revision of treatment regimens and rapid upscaling of DOTS-plus initiative.
    Bhargava A; Jain Y
    Natl Med J India; 2008; 21(4):187-91. PubMed ID: 19267041
    [No Abstract]   [Full Text] [Related]  

  • 16. Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.
    van Altena R; Akkerman OW; Alffenaar JC; Kerstjens HA; Magis-Escurra C; Boeree MJ; van Soolingen D; de Lange WC; Bolhuis MS; Hoefsloot W; de Vries G; van der Werf TS
    Eur Respir J; 2016 Dec; 48(6):1800-1802. PubMed ID: 27824604
    [No Abstract]   [Full Text] [Related]  

  • 17. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
    Chee CBE; KhinMar KW; Sng LH; Jureen R; Cutter J; Lee VJM; Wang YT
    Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28798092
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of drug-resistant tuberculosis.
    Lange C; Dheda K; Chesov D; Mandalakas AM; Udwadia Z; Horsburgh CR
    Lancet; 2019 Sep; 394(10202):953-966. PubMed ID: 31526739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future may not be so dark.
    Espinal MA; Gupta R; Raviglione MC
    Int J Tuberc Lung Dis; 2001 Sep; 5(9):787-8. PubMed ID: 11573888
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy for tuberculosis. American Thoracic Society.
    Singh V
    Indian Pediatr; 1995 Aug; 32(8):943-4. PubMed ID: 8635851
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.